{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_16", "document_index": 84, "latency_s": 0.7780542999971658, "prompt_toks": 6422, "completion_toks": 80, "relevance_score": 4.97571e-06}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    United States: Cannabidiol is legal under the 2018 Farm Bill[37]. The rest of the cannabis plant (anything with more than 0.3% Delta-9-THC) is still under Schedule I of the Controlled Substances Act.[citation needed]\n\nExternal links\n\nCannabidiol (Wikipedia)\n\nCannabidiol (Isomer Design)\n\nCannabidiol (Drugs-Forum)\n\nProject CBD\n\nLiterature\n\nMechoulam, R., Peters, M., Murillo-Rodríguez, E., & Hanuš, L.O. (2007). Cannabidiol--recent advances. Chemistry & Biodiversity, 4 8, 1678-92.\n\nMechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. The Journal of Clinical Pharmacology, 42(S1).\n\nDevinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., ... & Martinez‐Orgado, J. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. https://doi.org/0.1111/epi.12631\n\nReferences\n\n\n                    Context: \n                    This chunk provides information on the legal status of cannabidiol in the United States, highlighting its legality under the 2018 Farm Bill and its classification under Schedule I of the Controlled Substances Act. It also includes external links and key literature references relevant to cannabidiol research and regulation, complementing the overall focus on CBD's effects, safety, and legal considerations within the full document.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_15", "document_index": 84, "latency_s": 0.8761873999901582, "prompt_toks": 6320, "completion_toks": 72, "relevance_score": 2.48248e-06}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Hong Kong: Illegal in Hong Kong since 1st February 2023, punishable by 7 years imprisonment.[33]\n\nNew Zealand: Cannabidiol is a controlled substance in New Zealand. However, by passing the Misuse of Drugs Amendment Regulations 2017 in September 2017, many of the restrictions currently imposed by the regulations are removed since then. The changes will mean that CBD products, where the level of other naturally occurring cannabinoids is less than 2% of the cannabinoid content, will be easier to access for medical use.[34]\n\nSwitzerland: Cannabidiol is not subject to the Narcotics Act in Switzerland because it does not produce a psychoactive effect. It is still subject to standard Swiss legislation.[35]\n\nUnited Kingdom: In 2016, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement that products containing CBD used for medical purposes are considered as a medicine subject to standard licensing requirements.[36]\n\n\n                    Context: \n                    This excerpt summarizes the legal status of cannabidiol (CBD) in various countries, highlighting recent regulations and enforcement. It details restrictions and allowances in Hong Kong, New Zealand, Switzerland, and the United Kingdom, providing key regulatory updates relevant to understanding CBD's legal landscape globally. This information is essential for users seeking legal guidance on CBD use across different jurisdictions.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Psilocybin & Psilocin Vault : Legal Status", "description": "Information on the legal status of Psilocybin & Psilocin.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/psilocybin/psilocybin_law.shtml", "drug": "Psilocybin", "cid": 10624, "substance": "psilocybin", "category": "CHEMICALS", "erowid_column": "Law", "char_count": 7199, "word_count": 1021, "doc_id": "doc_219", "num_chunks": 9, "chunk_id": "219::chunk_6", "document_index": 219, "latency_s": 1.2673293999978341, "prompt_toks": 2082, "completion_toks": 83, "relevance_score": 2.48248e-06}, "content": "Drug: Psilocybin | cid: 10624\nSource: erowid | Source description: Information on the legal status of Psilocybin & Psilocin.\nErowid name: psilocybin\nCategory: CHEMICALS\nField: Law\n\n                    Text: \n                    Department personnel, shall use any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the use and possession of Entheogenic Plants by adults; [... and ...] RESOLVED That the Mayor and City Council hereby declare that it shall be the policy of the City of Oakland that the investigation and arrest of adult persons for planting, cultivating, purchasing, transporting, distributing, engaging in practices with, and/or possessing Entheogenic Plants or plant compounds on the Federal Schedule 1 list shall be amongst the lowest law enforcement priority for the City of Oakland; [...]\" (last updated June 4 2019)\n\n\n                    Context: \n                    This excerpt details Oakland's local policy prioritizing decriminalization and low enforcement regarding entheogenic plants, including psilocybin mushrooms, within the broader context of the webpage's focus on drug legality and law reform at state and international levels. It highlights Oakland's specific resolution on deprioritizing investigations and arrests related to Schedule 1 entheogenic plants, emphasizing its significance in current legal and activism discussions.\n                "}
